GlassScriptPhysician profile
Hsiao Fen Chen
NPI 1366483497
$16,960.69
in general payments reported to CMS, 2019-2025
39 companies · $2,281 in 2025
The $2,281 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,180 · 2020: $1,839 · 2021: $3,132 · 2022: $2,954 · 2023: $1,638 · 2024: $1,937 · 2025: $2,281.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,856.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,856.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,903.15 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Amgen INC. | $1,863.04 | 2019-2025 | Repatha, Otezla, Evenity |
| Abbvie INC. | $1,360.58 | 2019-2025 | Linzess, Viberzi, Ubrelvy |
| Takeda Pharmaceuticals U.S.A., INC. | $1,346.78 | 2019-2025 | Trintellix |
| Bayer Healthcare Pharmaceuticals INC. | $1,308.27 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,017.15 | 2019-2024 | Jardiance |
| Glaxosmithkline, LLC. | $929.35 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Pfizer INC. | $905.87 | 2019-2025 | |
| Lilly USA, LLC | $770.85 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $717.65 | 2019-2025 | Rybelsus, Ozempic |
| Allergan, INC. | $601.13 | 2019-2020 | |
| Amarin Pharma, INC. | $528.66 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $449.94 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $426.43 | 2019-2025 | |
| Radius Health, INC. | $418.19 | 2019-2024 | Tymlos |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hsiao Fen Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.